ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,084Medicare Part D Prescriptions Filled, Including Refills

Rank: 123 out of 2680

$985K Total Retail Price of All Prescriptions

Rank: 65 out of 2680

649 Patients Receiving at Least One Drug in Part D
46%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

40% of this provider’s 649 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

5% of this provider’s 4,219 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

42% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$89 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
HYDROCODONE-ACETAMINOPHEN 877 214 S3 1 13
CARISOPRODOL 598 100 R 2 175
ZOLPIDEM TARTRATE 502 143 3 17
SYMBICORT 310 95 4 114
NEXIUM 297 103 5 19
EXFORGE 255 114 6 139
ATORVASTATIN CALCIUM 249 123 7 10
CLONIDINE HCL 243 64 8 84
SINGULAIR 230 80 9 64
CRESTOR 219 113 10 15
AMLODIPINE BESYLATE-BENAZEPRIL 207 94 11 58
LYRICA 180 46 12 107
MONTELUKAST SODIUM 165 54 13 134
PROAIR HFA 165 39 13 52
PREDNISONE 161 69 15 45
LANTUS SOLOSTAR 154 67 16 68
GLYBURIDE-METFORMIN HCL 154 59 R 16 96
TRAMADOL HCL 144 45 18 33
BYSTOLIC 141 57 19 104
AZITHROMYCIN 140 33 20 40
LEVOTHYROXINE SODIUM 135 83 21 4
HYDROXYZINE HCL 132 43 R 22 212
NASONEX 132 45 22 206
ZETIA 131 48 24 69
OMEPRAZOLE 121 62 25 2
ZOSTAVAX 120 113 26 229
SPIRIVA 96 50 27 36
CELEBREX 88 31 28 75
CLOPIDOGREL 88 54 28 30
RAMIPRIL 85 54 30 49
FUROSEMIDE 80 48 31 7
METFORMIN HCL 80 30 31 6
ESCITALOPRAM OXALATE 79 36 33 82
DIOVAN 79 20 33 26
CYMBALTA 73 0 35 56
AMOX TR-POTASSIUM CLAVULANATE 70 28 36 145
ALCOHOL SWABS 68 25 37 181
ACETAMINOPHEN-CODEINE 66 44 S3 38 156
PROVENTIL HFA 66 25 38 288
VENTOLIN HFA 65 34 40 61
BUPROPION XL 61 12 41 233
SEROQUEL XR 60 0 42 454
AMLODIPINE BESYLATE 57 27 43 3
FAMOTIDINE 56 21 44 65
PLAVIX 56 34 44 41
CHANTIX 56 17 44 542
NAMENDA 56 51 44 43
HYDROCHLOROTHIAZIDE 54 27 48 9
METHOCARBAMOL 54 12 R 48 342
CIPROFLOXACIN HCL 51 16 50 85
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 7, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.